share_log

Altimmune | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-TIAA-CREF Investment Management, LLC(2.88%),Teachers Advisors, LLC(0.32%), etc.

Altimmune | SC 13G/A：超過5%持股股東披露文件(修正)-TIAA-CREF Investment Management, LLC(2.88%),Teachers Advisors, LLC(0.32%)等

美股sec公告 ·  02/14 11:37
Moomoo AI 已提取核心訊息
On December 31, 2023, Altimmune Inc., a biopharmaceutical company, was the subject of a Schedule 13G filing with the Securities and Exchange Commission (SEC), indicating changes in ownership by significant investors. The filing was made by three investment management firms: Nuveen Asset Management, LLC (NAM), TIAA-CREF Investment Management, LLC (TCIM), and Teachers Advisors, LLC (TAL), all organized under the laws of Delaware. According to the amendment, NAM reported ownership of 6,679 shares, TCIM reported 1,549,364 shares, and TAL reported 171,273 shares of Altimmune's common stock. Collectively, these firms now beneficially own 1,727,316 shares, representing 3.21% of the company's class of common stock. The filing, dated February 14, 2024, asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Altimmune Inc.
On December 31, 2023, Altimmune Inc., a biopharmaceutical company, was the subject of a Schedule 13G filing with the Securities and Exchange Commission (SEC), indicating changes in ownership by significant investors. The filing was made by three investment management firms: Nuveen Asset Management, LLC (NAM), TIAA-CREF Investment Management, LLC (TCIM), and Teachers Advisors, LLC (TAL), all organized under the laws of Delaware. According to the amendment, NAM reported ownership of 6,679 shares, TCIM reported 1,549,364 shares, and TAL reported 171,273 shares of Altimmune's common stock. Collectively, these firms now beneficially own 1,727,316 shares, representing 3.21% of the company's class of common stock. The filing, dated February 14, 2024, asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Altimmune Inc.
2023年12月31日，生物製藥公司Altimmune Inc. 成爲向美國證券交易委員會（SEC）提交的附表13G文件的主體，這表明重要投資者的所有權發生了變化。該文件由三家投資管理公司提交：Nuveen資產管理有限責任公司（NAM）、TIAA-CREF投資管理有限責任公司（TCIM）和Teachers Advisors, LLC（TAL），均根據特拉華州法律成立。根據該修正案，不結盟運動報告了6,679股股票的所有權，TCIM報告了1,549,364股股票，TAL報告了171,273股Altimmune普通股。這些公司現在共擁有1,727,316股股票，佔公司普通股類別的3.21％。這份日期爲2024年2月14日的文件稱，這些股票是在正常業務過程中收購的，不是爲了改變或影響Altimmune Inc.的控制權。
2023年12月31日，生物製藥公司Altimmune Inc. 成爲向美國證券交易委員會（SEC）提交的附表13G文件的主體，這表明重要投資者的所有權發生了變化。該文件由三家投資管理公司提交：Nuveen資產管理有限責任公司（NAM）、TIAA-CREF投資管理有限責任公司（TCIM）和Teachers Advisors, LLC（TAL），均根據特拉華州法律成立。根據該修正案，不結盟運動報告了6,679股股票的所有權，TCIM報告了1,549,364股股票，TAL報告了171,273股Altimmune普通股。這些公司現在共擁有1,727,316股股票，佔公司普通股類別的3.21％。這份日期爲2024年2月14日的文件稱，這些股票是在正常業務過程中收購的，不是爲了改變或影響Altimmune Inc.的控制權。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息